The U.S. Food and Drug Administration has questioned the evidence as demand for the compounds increases.
Published On 22 Jul 2026
Peptides, a class of compounds increasingly marketed as wellness treatments, have surged in popularity, moving from niche bodybuilding and biohacking circles to widespread promotion for weight loss, longevity, and other health claims.
Concerns about their safety and efficacy have prompted U.S. regulators to consider whether certain peptides should be made available through licensed pharmacies.
The Pharmacy Compounding Advisory Committee of the U.S. Food and Drug Administration (FDA) will convene on Thursday and Friday to determine whether the seven peptides may be compounded by licensed pharmacies for patients with prescriptions.
Peptides are short chains of amino acids that naturally occur in the body and regulate diverse biological processes. While peptide‑based medicines such as GLP‑1 receptor agonists (e.g., Ozempic, Wegovy) have become household names, the seven peptides under review constitute a distinct group marketed for various conditions.
The peptides under review include BPC‑157, TB‑500, and KPV, which are promoted for ulcerative colitis, wound healing, and inflammation, as well as other compounds marketed for obesity, migraines, chronic pain, insomnia, and opioid withdrawal.
The review follows heightened mainstream interest driven by social‑media influencers, the “looksmaxxing” beauty trend, and repeated endorsements by Health Secretary Robert F. Kennedy Jr., who reports personal use with “really good effect” and contends that regulatory restrictions have driven consumers into an unregulated market.
Industry groups contend that the growing demand underscores the need for the FDA to facilitate compounding by licensed pharmacies, which could improve prescription oversight and quality control.
The composition of the advisory committee is also controversial. Seven of the committee’s 14 members have reported affiliations with businesses or clinics offering peptide therapies, including physicians who operate such clinics, promote peptides on social media, and a pharmacist and Tennessee State Senator Bobby Harshbarger, whose family owns a pharmacy that sells compounded medications. His mother, Representative Diana Harshbarger, urged Kennedy last year to relax FDA restrictions on peptides.
The Department of Health and Human Services has defended the panel, stating that all members have undergone the required ethics review and that any individuals failing federal ethics requirements were removed from consideration.
Although the panel’s recommendations are non‑binding, they are expected to influence the FDA’s final decision.